

2M+_{VERIFIED HCPs} Across 150 Key Therapeutic Areas

Oncology

In the last three years, Konovo has completed more than **2,530 Oncology projects**, delivering **146,135** completes for our clients. From these studies, we pulled together some interesting statistics which we have summarized below.

collection, aiming to share our expertise with our clients every step of the research process – from initial proposal to final data deliverable. Throughout the process, we employ a specialized suite of proprietary technologies that are always evolving to address the dynamic needs of our clients.

At Konovo, our singular focus is on healthcare data

Choose Konovo and leverage unparalleled panel access, powerful customized tools, and unmatched industry know-how.





What we can achieve: Global Access

respondents spanning the Americas, Canada, Europe and Asia. Konovo's unmatched reach, backed by our rigorous quality controls, provides access to representative samples you can trust.

Our panel of Physicians and Allied Healthcare Professionals is known for quality, with








'.v. j

1,020



USA


All and Hodgkin's

Germany



Italy

Medical-oncologists



48%

EUROPE

All and Hodgkin's

	32%		39%
Brain, Small Cell, Thyroid		Brain, Small Cell, Thyroid	
	62%		59%
Breast		Breast	
	66%		73%
CML and Myeloma	51%	CML and Myeloma	62%
Colon and Rectal		Colon and Rectal	
	23%		56%
Esophageal and Gastric		Esophageal and Gastric	
	57%		54%
Liver (HCC) and Pancreatic	2004	Liver (HCC) and Pancreatic	400/
	29%		49%
MDS and AML	50%	MDS and AML	73%
Melanoma		Melanoma	
	50%		55%
NHL and CLL		NHL and CLL	
	44%		34%
Non-small Cell Lung		Non-small Cell Lung	
	74%		75%
Ovarian and Uterine	53%	Ovarian and Uterine	62%
Ovarian and Cervical		Ovarian and Cervical	
	61%		60%
Prostate and Bladder		Prostate and Bladder	
	59%		52%
Prostate and Renal Cell		Prostate and Renal Cell	

Sarcomas

47%

60%

Sarcomas